Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-1 trials

Autor: N. N. J. Rommelse, A. R. Müller, Kit C.B. Roes, J. R. Zinkstok, E. de Rooij-Askes, Erik Boot, A. M. van Eeghen, P. M. van de Ven, C. Linders, Frits A. Wijburg

Publikováno v: Orphanet Journal of Rare Diseases, 16(1):380. BioMed Central
Orphanet Journal of Rare Diseases, 16, 1
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-9 (2021)
Orphanet Journal of Rare Diseases, 16
Orphanet Journal of Rare Diseases
Müller, A R, Zinkstok, J R, Rommelse, N N J, van de Ven, P M, Roes, K C B, Wijburg, F A, de Rooij-Askes, E, Linders, C, Boot, E & van Eeghen, A M 2021, ' Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-1 trials ', Orphanet Journal of Rare Diseases, vol. 16, no. 1, 380 . https://doi.org/10.1186/s13023-021-02003-z
Orphanet journal of rare diseases, 16(1):380. BioMed Central

Background Smith–Magenis syndrome (SMS) is a rare genetic neurodevelopmental disorder characterized by intellectual disability and severe behavioural and sleep disturbances. Often, patients with SMS are diagnosed with attention-deficit/hyperactivit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22006ad57c247d05c5d485a94d22a674
https://research.vumc.nl/en/publications/d78993ce-0f37-44fc-9056-5e3330518966